These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3587405)

  • 21. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 22. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
    Lieberman A; Le Brun Y; Boal D; Zolfaghari M
    Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of anticholinergic antiparkinson agents against adverse drug reactions in a psychiatric department. A quality assurance project].
    Mikkelsen VR
    Ugeskr Laeger; 1998 Jul; 160(29):4323-5. PubMed ID: 9679438
    [No Abstract]   [Full Text] [Related]  

  • 24. [Sleepiness attacks while driving: adverse effects of new antiparkinson drugs].
    Miranda M; Díaz V; Venegas P; Villagra R
    Rev Med Chil; 2001 May; 129(5):585-6. PubMed ID: 11464545
    [No Abstract]   [Full Text] [Related]  

  • 25. [Abnormal diurnal somnolence, "sleep attacks" and antiparkinson drugs].
    Rascol O; Ferreira J; Montastruc JL
    Rev Neurol (Paris); 2001 Oct; 157(10):1313-23. PubMed ID: 11885528
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 27. Effective strategies in the management of Parkinson's disease.
    Wills AJ
    Hosp Med; 1998 Apr; 59(4):287-90. PubMed ID: 9722367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Welcome news about levodopa, but uncertainty remains.
    Fahn S
    Ann Neurol; 1998 May; 43(5):551-4. PubMed ID: 9585348
    [No Abstract]   [Full Text] [Related]  

  • 30. Heat dyscontrol syndrome in patients receiving antipsychotic, antidepressant and antiparkinson drug therapy.
    Reimer DR; Mohan J; Nagaswami S
    J Fla Med Assoc; 1974 Jul; 61(7):573-4. PubMed ID: 4152488
    [No Abstract]   [Full Text] [Related]  

  • 31. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Revision of the treatment strategy in Parkinson's disease].
    Ned Tijdschr Geneeskd; 1986 Jul; 130(28):1291-3. PubMed ID: 3748207
    [No Abstract]   [Full Text] [Related]  

  • 34. [The treatment of Parkinson disease].
    Jiménez-Jiménez FJ
    Med Clin (Barc); 1999 Feb; 112(7):257-8. PubMed ID: 10220753
    [No Abstract]   [Full Text] [Related]  

  • 35. Iatrogenesis imperfecta.
    Friedman JH
    Med Health R I; 2002 Jul; 85(7):198. PubMed ID: 12182087
    [No Abstract]   [Full Text] [Related]  

  • 36. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Ben-Shlomo Y; Lees A;
    Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug treatment of Parkinson's disease.
    Callaghan N
    Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850
    [No Abstract]   [Full Text] [Related]  

  • 38. Drugs for Parkinson's Disease.
    Treat Guidel Med Lett; 2004 Jun; 2(22):41-6. PubMed ID: 15529113
    [No Abstract]   [Full Text] [Related]  

  • 39. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R
    Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract]   [Full Text] [Related]  

  • 40. [Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):245-6. PubMed ID: 16038123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.